Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature

Abstract Background HER2 is a member of the ERBB family of receptor tyrosine kinases, and HER2 mutations occur in 1–4% of non-small cell lung cancer (NSCLC) as an oncogenic driver mutation. We found a rare mutation of HER2 p.Asp769Tyr in NSCLC. Case presentation We presented a case of a 68-year-old...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Huanhuan Xu, Qi Liang, Xian Xu, Shanyue Tan, Sumeng Wang, Yiqian Liu, Lingxiang Liu
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Accès en ligne:https://doaj.org/article/d93f651f018a4241a32241d207e7578e
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!